169751-73-9 Usage
Description
Tos-PEG5-CH2CO2t-butyl ester, also known as Tos-PEG5-CH2CO2tBu, is a PEG (polyethylene glycol) linker that features a t-butyl ester and a tosyl group. This molecule is designed to enhance solubility in aqueous media due to the hydrophilic PEG spacer. The t-butyl protected carboxyl group can be deprotected under acidic conditions, allowing for further chemical modifications or reactions. The tosyl group serves as an excellent leaving group for nucleophilic substitution reactions, making it a versatile component in various chemical and biological applications.
Uses
Used in Chemical Synthesis:
Tos-PEG5-CH2CO2t-butyl ester is used as a PEG linker for chemical synthesis, providing a hydrophilic spacer that increases solubility in aqueous media. The t-butyl ester allows for selective deprotection under acidic conditions, enabling the introduction of various functional groups or molecules.
Used in Bioconjugation:
In the field of bioconjugation, Tos-PEG5-CH2CO2t-butyl ester is used as a versatile PEG linker to attach biologically active molecules, such as peptides, proteins, or small molecules, to a PEG chain. The tosyl group acts as a good leaving group for nucleophilic substitution reactions, facilitating the conjugation process.
Used in Drug Delivery Systems:
Tos-PEG5-CH2CO2t-butyl ester is used as a component in drug delivery systems, particularly for the development of targeted therapies. The PEG linker can improve the solubility and stability of drug molecules, while the t-butyl ester and tosyl group can be utilized for attaching the drug to the PEG chain or for further functionalization.
Used in Material Science:
In material science, Tos-PEG5-CH2CO2t-butyl ester is used as a building block for the development of novel materials with enhanced properties. The PEG linker can be incorporated into polymers, hydrogels, or other materials to improve their hydrophilicity, biocompatibility, and responsiveness to environmental stimuli.
Used in Analytical Chemistry:
Tos-PEG5-CH2CO2t-butyl ester is used as a reagent in analytical chemistry for the modification of surfaces or the development of new chromatographic stationary phases. The PEG linker can provide improved separation and detection of various analytes, while the t-butyl ester and tosyl group can be used for immobilization or further functionalization.
Check Digit Verification of cas no
The CAS Registry Mumber 169751-73-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,7,5 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 169751-73:
(8*1)+(7*6)+(6*9)+(5*7)+(4*5)+(3*1)+(2*7)+(1*3)=179
179 % 10 = 9
So 169751-73-9 is a valid CAS Registry Number.
169751-73-9Relevant articles and documents
Gene coding compound library starting head fragment compound and application thereof in gene coding compound library synthesis
-
Paragraph 0059-0061, (2021/11/14)
The invention provides a gene coding compound library starting head fragment compound and application thereof in synthesis of a gene coding compound library, and has good universality. The method is mild in condition, convenient to operate and high in yie
Lenalidomide-based small-molecular compound targeting to EGFR protein degradation, and preparation and application thereof
-
Paragraph 0050; 0061; 0068; 0069; 0070, (2020/09/09)
The invention relates to a lenalidomide-based small-molecular compound targeting to EGFR protein degradation, and preparation and application thereof, and provides a compound targeting to ubiquitination induced EGFR protein degradation and shown as a form
Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound
-
Paragraph 0509-0512, (2020/12/01)
The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.
